CXCL8 and primary cutaneous T-cell non-Hodgkin lymphoma: Since the HDAC inhibition by vorinostat has been very effective in the treatment of CTCL [14-19], in this study, we have investigated whether vorinostat induces the CXCL8 expression in CTCL Hut-78 cells, as well as in the widely used cervical cancer HeLa cells.